Vident Investment Advisory’s Sarepta Therapeutics SRPT Stock Holding History

Vident Investment Advisory’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,694	Closed	-$209K	–	1232
2021 Q2	$209K	Sell	2,694 -3,483	-56%	-$264K	0.01%	1042
2021 Q1	$460K	Sell	6,177 -1,787	-22%	-$165K	0.02%	811
2020 Q4	$1.36M	Buy	7,964 +432	+6%	+$64K	0.06%	445
2020 Q3	$1.06M	Buy	7,532 +1,574	+26%	+$239K	0.05%	471
2020 Q2	$955K	Buy	5,958 +3,554	+148%	+$484K	0.05%	492
2020 Q1	$235K	Buy	2,404 +207	+9%	+$23.7K	0.02%	729
2019 Q4	$284K	Buy	+2,197	New	+$222K	0.02%	647
2019 Q2	–	Sell	-1,964	Closed	-$234K	–	625
2019 Q1	$234K	Sell	1,964 -593	-23%	-$76.2K	0.01%	683
2018 Q4	$279K	Sell	2,557 -160	-6%	-$20K	0.02%	724
2018 Q3	$439K	Buy	+2,717	New	+$371K	0.02%	745

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vident Investment Advisory's SRPT Position: Q3 2021 in Review

Vident Investment Advisory sold out of Sarepta Therapeutics (SRPT) in Q3 2021, closing a stake of 2,694 shares — an estimated $209K sold.

Vident Investment Advisory first reported a position in SRPT in Q3 2018 and held it in 10 quarters. The position peaked at $1.36M in Q4 2020. 306 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

Vident Investment Advisory reported no remaining Sarepta Therapeutics position as of Q3 2021 after selling out during the quarter.
Vident Investment Advisory sold 2,694 Sarepta Therapeutics shares in Q3 2021, an estimated $209K.
Vident Investment Advisory first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 10 quarters.
Vident Investment Advisory's Sarepta Therapeutics position peaked at $1.36M in Q4 2020.
306 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on Vident Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.